Botulinum Toxin for Painful Cutaneous Leiomyomas

肉毒杆菌毒素治疗疼痛性皮肤平滑肌瘤

• 批准号: 8553022
• 负责人: Heidi Kong
• 金额: $ 5.91万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8553022
• 关键词: Acetylcholine; Acetylcholinesterase; Adverse effects; Botulinum Toxins; Calcitonin Gene-Related Peptide; Cancer Patient; Clinical; Cutaneous Leiomyoma; Double-Blind Method; Etiology; Hair follicle structure; Hereditary Leiomyomatosis and Renal Cell Cancer; Injection of therapeutic agent; Leiomyoma; Lesion; Mediating; Mus; Muscle; Muscle Contraction; Nerve; Nerve Fibers; Neural Conduction; Neuropeptides; Pain; Pain Nature; Pathway interactions; Patients; Pilot Projects; Placebo Control; Protocols documentation; Quality-of-Life Assessment; Reporting; Research Design; Role; Staining method; Stains; Study Subject; Symptoms; Travel; United States National Institutes of Health; Visit; alpha-adrenergic receptor; base; diaries; hair erector muscle; nerve supply; pressure; response

Our pilot study of botulinum toxin-A for painful skin leiomyomas will evaluate whether patients receive pain relief after injection. Given the often subjective nature of pain, we have designed the study in a placebo-controlled and double-blinded fashion. For the duration of the study, subjects will rate their pain using standardized pain scoring scales at study visits and through a pain diary. Subjects will also complete quality of life assessments. Due to the rarity of this condition and difficulty for patients to travel to the NIH Clinical Center for protocol participation, accrual has been slow.

我们的肉毒杆菌毒素-A治疗疼痛皮肤肌瘤的初步研究将评估患者在注射后是否得到疼痛缓解。考虑到疼痛的主观性质，我们以安慰剂对照和双盲的方式设计了这项研究。在研究期间，受试者将在研究访问时使用标准化的疼痛评分表并通过疼痛日记对他们的疼痛进行评级。受试者还将完成生活质量评估。由于这种情况很罕见，而且患者很难前往NIH临床中心参加治疗方案，因此累积一直很慢。